Trial Profile
Phase II Trial to Evaluate Trametinib in Patients With Advanced NF1-mutant Non-small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Trametinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Nov 2019 Status changed from recruiting to discontinued.
- 16 Feb 2018 Status changed from not yet recruiting to recruiting.
- 12 Jan 2018 Planned initiation date changed from 8 Dec 2017 to 1 Jul 2018.